Peloton Therapeutics officially withdraws $150 million IPO following Merck acquisition

Shutterstock photo

Peloton Therapeutics, a Phase 2 biotech developing small-molecule HIF-2a inhibitors for kidney cancer, officially withdrew its plans for an initial public offering on Wednesday. In May of this year, Peloton announced that it would be acquired by Merck for $1.05 billion in cash, plus up to $1.15 billion in milestone payments; the announcement came one day before it was scheduled to price. It had originally filed to raise $150 million for a fully-diluted market cap of $742 million.

The Dallas, TX-based company was founded in 2010 and had planned to list on the Nasdaq under the symbol PLTX. J.P. Morgan, Citi and Jefferies were set to be the joint bookrunners on the deal.

The article Peloton Therapeutics officially withdraws $150 million IPO following Merck acquisition originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?